Molecular imaging and immunotherapy

Laura Evangelista¹,²

Abstract

The utility of positron emission tomography (PET) for the evaluation of response to immunotherapy has been considered a hot topic, particularly in the last 2 to 3 years. Different experiences have been collected in clinical practice, with 18F-Fluorodeoxyglucose (FDG) PET/computed tomography (CT), particularly in patients affected by lymphoma, malignant melanoma, and lung cancer. It has been tested in different settings of disease, from the prediction to the prognosis relative to the response to immunotherapy. In the present mini-review, some evidence is reported about the role of FDG PET/CT in patient candidates to or treated with immunotherapy.

Keywords

Immunotherapy, FDG, PET/CT, lung cancer, melanoma

Date received: 4 November 2019; revised: 18 November 2019; accepted: 16 December 2019

18F-Fluorodeoxyglucose in patient candidates to (FDG) positron emission tomography (PET) has been extensively used for the evaluation of response to conventional chemotherapy, both in the interim and after the end of all the cycles, demonstrating a significant impact on patient management and prognosis.¹⁻⁴ However, until now, few preliminary data are available about the utility of PET for the evaluation of response to immunotherapy.⁵ Different experiences have been collected in the recent years in clinical practice with FDG PET/computed tomography (CT), particularly in patients affected by lymphoma,⁶⁻⁷ malignant melanoma,⁸⁻¹² and lung cancer.¹³⁻¹⁵ Its role has been tested in different setting of disease, such as the prediction, the assessment, and the prognosis relative to the response to immunotherapy.

In the study by Grizzi et al.,¹⁶ FDG PET/CT was able to identify lung cancer patients who will respond to immunotherapy by using the semiquantitative analysis (sensitivity of 88.9% in case of a SUVmax < 17.1 in the index lesion for the identification of the fast progression after 8 weeks of therapy). Similarly, Evangelista et al.¹⁷ demonstrated that the sum of the data obtained by semiquantitative PET analysis was able to predict the responsiveness to immunotherapy in lung cancer, based on the patient’s gender.

For the assessment of response to immunotherapy, the experiences are variable. In 2016, the Lugano criteria for lymphoma were refined as LYRIC (Lymphoma Response to Immunomodulatory Therapy Criteria) introducing the concept of indeterminate response, for those cases with “delayed response” or “pseudo-progression,” which may be related to recruitment of immune cells to disease site.⁶ FDG PET/CT has been used for the indeterminate response in different clinical trials, particularly to confirm complete response or progressive disease.⁷ However, it also seems to be useful in cases of patients with stable or unclear response to therapy at CT imaging, by using RECIST¹.¹ (Response Evaluation Criteria in Solid Tumors) or iRECIST (immunoRECIST) criteria for the interpretation of the morphological images.¹¹ In melanoma patients, it has been demonstrated that the response to immunotherapy can be predicted with a sensitivity of 100% and a specificity of 93%⁸,¹⁰ (Figure 1). Similarly, the inclusion of a third PET scan, after 4 weeks from the second one (usually performed after 2 months from the start of immunotherapy) was able to differentiate between unconfirmed and confirmed progressive disease.

¹Nuclear Medicine Unit, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy
²Nuclear Medicine Unit, Department of Medicine – DIMED, University of Padua, Padua, Italy

Corresponding author:
Laura Evangelista, Nuclear Medicine Unit, Department of Medicine – DIMED, University of Padua, Via Giustiniani 2, Padua, 35128, Italy.
Email: laura.evangelista@unipd.it

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Some efforts have been made in recent years to identify specific criteria for the definition of response to therapy with FDG PET/CT (Table 1). The PERCIMT (PET Response Evaluation Criteria for Immunotherapy) criteria (by considering both morphological and functional size of the lesions) were tested at interim evaluation, after two cycles of immunotherapy in patients with melanoma, and were compared with the EORTC (European Organisation for Research and Treatment of Cancer) criteria. The PERCIMT showed a significantly higher sensitivity than the EORTC in predicting the clinical benefit (93.4% vs. 64.5%, respectively); however, it showed a lower specificity in predicting no clinical benefit. The PECRIT, a mix of RECIST 1.1 and PERCIST criteria, predicted the response to immunotherapy at 21 to 28 days, with 100% sensitivity, 93% specificity, and 95% accuracy. Finally, the above mentioned iPERCIST criteria were assessed in 28 patients affected by lung cancer, and showed a significant reclassification than iRECIST in 39% of cases.

FDG PET/CT has always been considered an optimal imaging instrument for the prognostic assessment. Patients with well-differentiated cancer has a better prognosis than those with scarcely differentiated tumors. Also, in patients undergoing immunotherapy, FDG PET/CT has reported some advantages in this setting. In the recent FIR-trial, lung cancer patients with a stable disease at CT RECIST analysis showed an early progression of disease at FDG PET/CT with a strong impact on the final prognosis. Therefore, in patients with a stable disease by CT-based RECIST criteria at week 6, metabolic response with PET further informs the outcome. In the study by Goldfarb et al., FDG PET monitoring with iPERCIST was an effective tool for discerning lung cancer patients who could benefit from treatment with nivolumab. The authors found that the 1-year survival rate was greater than 90% in responders and 11% for non-responders. A later FDG PET/CT (after 1 year from the end of immunotherapy), also may be considered a useful prognostic instrument in patients with malignant melanoma.

FDG is trapped in tissues with high glycolytic activity and thus it is not specific. Therefore, a high rate of false positive findings would be found, especially in patients undergoing immunotherapy, due to the activation of the immune system. Patient preparation and the physician’s interpretation of FDG PET/CT images during immunotherapy is essential for defining the response to therapy. First, the differential diagnosis between pseudo-progression and hyper-progression would be difficult to assess by using only two PET/CT scans; therefore, a third scan is warranted, as reported by Goldfarb et al. and Cho et al. Second, immune-related side effects (colitis, thyroiditis, others) should be taken into account for the interpretation.

**Figure 1.** A 69-year-old man affected by a T/NK nasal type lymphoma treated with immunotherapy (Pembrolizumab). PET/CT scan showed a partial response to immunotherapy. The patient was later submitted to radiotherapy. PET/CT: positron emission tomography/computed tomography.
of FDG PET/CT images, as they are associated with a high rate of false positive findings in the colon, thyroid, lung, and others. However, Eshghi et al. reported that the appearance of FDG uptake in the thyroid gland during immunotherapy was associated with the development of immune-related adverse events and therefore has a potential response to immunotherapy, due to the activation of the immune system (Figure 2). In order to overpass the limitations of FDG, alternative radiopharmaceuticals have been tested in preclinical studies, such as anti-PD-L1, anti-CTL-4, and similar, radiolabeled with radioisotope for single-photon emission computed tomography (SPECT; i.e. 111In) or PET imaging (i.e. 64Cu or 18F). The preliminary data are encouraging for the in vivo evaluation of PD-L1 expression in the lesions (both primary and metastasized). To date, only one study is available regarding the role of 99mTc-labeled anti-PD-L1 sdAb SPECT/CT in patients affected by lung cancer. The results demonstrated the feasibility and safety of this new agent, which would be used for the selection of patients who will respond to immunotherapy, and for monitoring the response to this treatment.

In conclusion, first, more clinical trials are necessary in order to identify the role of FDG PET/CT in patient

**Table 1. Suggested criteria for the interpretation of images.**

| Criteria name, ref | Neoplasm | Therapy | Interpretation |
|-------------------|----------|---------|----------------|
| iPERCIST, 15      | Lung cancer | Immunotherapy | CMR: Complete resolution of FDG uptake in all lesions  
PMR: Þ 30% Reduction of the SULpeak and an absolute drop of 0.8 SULpeak units  
PMD: unconfirmed progressive metabolic disease (UPMD) and confirmed progressive metabolic disease (CPMD).  
UPMD was a PMD at SCAN-2, and CPMD was an UPMD confirmed 4 weeks later at SCAN-3. In iPERCIST, SCAN-3 is compared to SCAN-2, and patients were classified as CMR, PMR, SMD, or CPMD according to PERCIST recommendations.  
SMD: not qualify for CMR, PMR, or PMD |
| PECRIT, 8         | Melanoma | Immunotherapy | CR: RECIST 1.1 (disappearance of all target lesions; reduction in short axis of target lymph nodes to < 1 cm; no new lesions) (clinical benefit)  
PR: RECIST 1.1 (decrease in target lesion diameter sum > 30%) (clinical benefit)  
SD: Does not meet the other criteria. Change in SULpeak of the hottest lesion of > 15% (clinical benefit)  
Change in SULpeak of the hottest lesion of < 15% (no clinical benefit)  
PD: RECIST 1.1 (increase in target lesion diameter sum of > 20% and at least 5 mm or new lesions) (no clinical benefit) |
| PERCIMT, 10       | Melanoma | Immunotherapy | CR: Complete resolution of all preexisting 18F-FDG-avid lesions; no new 18F-FDG-avid lesions (clinical benefit)  
PR: Complete resolution of some preexisting 18F-FDG-avid lesions. No new, 18F-FDG avid lesions (clinical benefit).  
SD: Neither PD nor PR/CR (clinical benefit)  
PD: Four or more new lesions of < 1 cm in functional diameter or three or more new lesions of > 1.0 cm in functional diameter or two or more new lesions of more than 1.5 cm in functional diameter (no clinical benefit) |
| Modified Lugano criteria and LYRIC criteria, 6 | Lymphoma | Immunotherapy | CR: PET/CT, score 1, 2, or 3 with or without a residual mass on Deauville criteria or on CT, target nodes/nodal masses must regress to < 1.5 cm in longest diameter.  
PR: PET-CT score 4 or 5 with reduced uptake compared with baseline and residual masses of any size. Or on CT Þ 50% decrease in sum of the product of the diameters of up to 6 target measurable nodes and extra nodal sites.  
PD: PET-CT score 4 or 5 with an increase in intensity of uptake from baseline and/or new FDG-avid foci consistent with lymphoma at interim or end-of-treatment assessment. In association with a new category of indeterminate response. |

CMR: complete metabolic response; CR: complete response; iPERCIST: Immuno Positron Emission Tomography Response Criteria in Solid Tumors; LYRIC: Lymphoma Response to Immunomodulatory Therapy Criteria; PECRIT: Criteria For Early Prediction Of Response To Immune Checkpoint Inhibitor Therapy; PERCIMT: PET Response Evaluation Criteria for Immunotherapy; PD: progressive disease; PET/CT: positron emission tomography/computed tomography; PMD: progressive metabolic disease; PMR: partial metabolic response; PR: partial response; SD: stable disease; SMD: stable metabolic response.
candidates to or undergoing immunotherapy; second, the standardization of criteria both for the definition of the optimal time between the immunotherapy cycle and the FDG PET/CT images, and for the definition of the response to therapy is necessary; and finally the potential benefit of PD-L1 theranostic imaging for the selection of patients should be tested in large cohorts of patients.

Declaration of conflicting interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Laura Evangelista https://orcid.org/0000-0002-5955-9488

References

1. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 2009; 50: 31S–42S. DOI: 10.2967/jnumed.108.057216.
2. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009; 50: 1S–10S. DOI: 10.2967/jnumed.108.057174.
3. Juweid ME and Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496–507.
4. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50: 122S–150S. DOI: 10.2967/jnumed.108.057307.
5. Aide N, Hicks RJ, Le Tourneau C, et al. FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging 2019; 46: 238–250. DOI: 10.1007/s00259-018-4171-4.
6. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128: 2489–2496. DOI: 10.1182/blood-2016-05-718528.
7. Kirienko M, Sollini M and Chiti A. Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy. Clin Transl Imaging. 2018; 6: 417–427. DOI: 10.1007/s40336-018-0294-7.
8. Cho SY, Lipson EJ, Im HJ, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med 2017; 58: 1421–1428. DOI: 10.2967/ jnumed.116.188839.
9. Anwar H, Sachpekidisa C, Winkler J, et al. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 2018; 45: 376–383. DOI: 10.1007/s00259-017-3870-6.
10. Sachpekidis C, Anwar H, Winkler J, et al. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 2018; 45: 1289–1296. DOI: 10.1007/s00259-018-3972-9.
11. Kong BY, Menzies AM, Saunders CA, et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res 2016; 29: 572–577. DOI: 10.1111/ pcmr.12503.
12. Tan AC, Emmett L, Lo S, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.

Figure 2. A 65-year-old woman with a cutaneous malignant melanoma treated with nivolumab. A partial response was noted after 4 months of treatment. The patient developed a thyroiditis relative to the immunotherapy.
13. Kaira K, Higuchi T, Naruse I, et al. Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. *Eur J Nucl Med Mol Imaging* 2018; 45: 56–66. DOI: 10.1007/s00259-017-3806-1.

14. Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with NSCLC. *J Thorac Oncol* 2018; 13: 1733–1742. DOI: 10.1016/j.jtho.2018.05.004.

15. Goldfarb L, Duchemann B, Chouahnia K, et al. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. *EJNMMI Res*. 2019; 9: 8. DOI: 10.1186/s13550-019-0473-1.

16. Grizzi F, Castello A and Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? *Eur J Nucl Med Mol Imaging* 2018; 45: 1072–1075. DOI: 10.1007/s00259-018-3988-1.

17. Evangelista L, Cuppari L, Menis J, et al. 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy. *Nucl Med Comm* 2019; 40: 802–807. DOI: 10.1097/MNM.0000000000001025.

18. Curioni-Fontecedro A, Ickenberg C, Franzen D, et al. Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab. *Ann Oncol* 2017; 28: 2040–2041. DOI: 10.1093/annonc/mdx233.

19. Eshghi N, Garland LL, Nia E, et al. 18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer. *J Nucl Med Technol* 2018; 46: 260–264. DOI: 10.2967/jnmt.117.204933.

20. Vaz SC, Capacho AS, Oliveira FP, et al. Radiopharmacology and molecular imaging of PD-L1 expression in cancer. *Clin Transl Imaging* 2018; 6: 429–439. DOI: 10.1007/s40336-018-0303-x.

21. Xing Y, Chand G, Liu C, et al. Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer. *J Nucl Med* 2019; 60: 1213–1220. Feb 22. pii: jnumed.118.224170. DOI: 10.2967/jnmed.118.224170.[Epub ahead of print]